E
Elliott Vichinsky
Researcher at Children's Hospital Oakland
Publications - 439
Citations - 32531
Elliott Vichinsky is an academic researcher from Children's Hospital Oakland. The author has contributed to research in topics: Thalassemia & Sickle cell anemia. The author has an hindex of 87, co-authored 424 publications receiving 29555 citations. Previous affiliations of Elliott Vichinsky include University of California, San Francisco & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography
Robert J. Adams,Virgil McKie,Lewis L. Hsu,B Files,Elliott Vichinsky,Charles H. Pegelow,Miguel R. Abboud,Dianne Gallagher,Abdullah Kutlar,Fenwick T. Nichols,Duane Bonds,Donald Brambilla +11 more
TL;DR: Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography.
Journal ArticleDOI
Pain in sickle cell disease. Rates and risk factors.
Orah S. Platt,Bruce D. Thorington,Donald Brambilla,Paul F. Milner,Wendell F. Rosse,Elliott Vichinsky,Thomas R. Kinney +6 more
TL;DR: The "pain rate" is a measure of clinical severity and correlates with early death in patients with sickle cell anemia over the age of 20, and even when the fetal hemoglobin level is low, one can predict that small increments in the level may have an ameliorating effect on the pain rate and may ultimately improve survival.
Journal ArticleDOI
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Elliott Vichinsky,Lynne Neumayr,A. Earles,Roger Williams,Evelyne T. Lennette,Deborah Dean,Bruce G. Nickerson,Eugene P. Orringer,Virgil McKie,Rita Bellevue,Charles Daeschner,E A Manci +11 more
TL;DR: A treatment protocol that included matched transfusions, bronchodilators, and bronchoscopy was evaluated and it was found that infection and fat embolism are underdiagnosed in patients with the syndrome.
Journal ArticleDOI
Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial.
Marilyn H. Gaston,Joel Verter,Gerald M. Woods,Charles H. Pegelow,John F. Kelleher,Presbury G,Harold S. Zarkowsky,Elliott Vichinsky,Rathi V. Iyer,Jeffrey S. Lobel +9 more
TL;DR: It is concluded that children should be screened in the neonatal period for Sickle cell hemoglobinopathy and that those with sickle cell anemia should receive prophylactic therapy with oral penicillin by four months of age to decrease the morbidity and mortality associated with pneumococcal septicemia.
Journal ArticleDOI
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
Martin H. Steinberg,Martin H. Steinberg,Franca B. Barton,Oswaldo Castro,Charles H. Pegelow,Samir K. Ballas,Abdullah Kutlar,Eugene P. Orringer,Rita Bellevue,Nancy F. Olivieri,James R. Eckman,Mala Varma,G. Ramirez,Brian Adler,Wally R. Smith,Timothy M. Carlos,Kenneth I. Ataga,Laura DeCastro,Carolyn Bigelow,Yogen Saunthararajah,Margaret Telfer,Elliott Vichinsky,Susan Claster,Susan Shurin,Kenneth Bridges,Myron A. Waclawiw,Duane Bonds,Michael L. Terrin +27 more
TL;DR: In a long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine whether hydroxyuraxurea attenuates mortality in Patients With SCA as discussed by the authors.